To elucidate the etiology and pathophysiology of spasmodic dysphonia, we examined the adductor branch of the recurrent laryngeal nerve and the lateral cricoarytenoid muscle from 9 consecutive patients with this disorder who were previously treated with botulinum toxin. Histologic examination revealed average muscle fiber diameters ranging from 21 to 57 μm. Botulinum toxin treatment-related muscle atrophy was observed up to 5 months after injection. Endomysial fibrosis was present in all samples. Histochemical analysis in 8 patients revealed type 2 fiber predominance in 7 patients and fiber type grouping in 2. Type-specific muscle fiber size changes were not present. Nerve samples were examined in plastic sections. In 8 patients the nerves contained homogeneous, large-diameter myelinated nerve fibers and sparse small fibers. One patient had a relatively increased proportion of small myelinated nerve fibers. Overall, the nerve fiber diameter was slightly larger in patients than in controls. These findings may implicate the central nervous system in the pathophysiology of adductor spasmodic dysphonia.
AronsonAEBrownIRLitinEMPearsonJS. Spastic dysphonia. II. Comparison with essential (voice) tremor and other neurologic and psychogenic dysphonias. J Speech Hear Disord1968;33:219–31.
2.
BlitzerALovelaceREBrinMFFahnSFinkME. Electromyographic findings in focal laryngeal dystonia (spastic dysphonia). Ann Otol Rhinol Laryngol1985;94:591–4.
3.
BlitzerABrinMFFahnSLovelaceRE. Clinical and laboratory characteristics of focal laryngeal dystonia: Study of 110 cases. Laryngoscope1988;98:636–40.
4.
Finitzo-HieberTFreemanFJGerlingIJDobsonLSchaeferSD. Auditory brainstem response abnormalities in adductor spasmodic dysphonia. Am J Otolaryngol1982;3:26–30.
5.
BielamowiczSLudlowCL. Effects of botulinum toxin on pathophysiology in spasmodic dysphonia. Ann Otol Rhinol Laryngol2000;109:194–203.
6.
DedoHH. Recurrent laryngeal nerve section for spastic dysphonia. Ann Otol Rhinol Laryngol1976;85:451–9.
7.
LudlowCL. Treatment of speech and voice disorders with botulinum toxin. JAMA1990;264:2671–5.
8.
BlitzerASulicaL. Botulinum toxin: Basic science and clinical uses in otolaryngology. Laryngoscope2001;111:218–26.
9.
IsshikiNTsujiDHYamamotoYIizukaY. Midline lateralization thyroplasty for adductor spasmodic dysphonia. Ann Otol Rhinol Laryngol2000;109:187–93.
10.
BerkeGSBlackwellKEGerrattBRVerneilAJacksonKSSercarzJA. Selective laryngeal adductor denervation-reinnervation: A new surgical treatment for adductor spasmodic dysphonia. Ann Otol Rhinol Laryngol1999;108:227–31.
11.
SchweizerVDorflJ. The anatomy of the inferior laryngeal nerve. Clin Otolaryngol1997;22:362–9.
12.
NguyenMJunien-LavillauroyC. Anatomy of the larynx, study of the anterior branch of the recurrent laryngeal nerve. Rev Laryngol Otol Rhinol (Bord)1990;111:153–5.
13.
DubowitzVBrookeMH. Muscle biopsy: A modern approach. Philadelphia, Pa: WB Saunders, 1973.
14.
HillelAD. The study of laryngeal muscle activity in normal human subjects and in patients with laryngeal dystonia using multiple fine-wire electromyography. Laryngoscope2001;111(suppl 97).
15.
BaranyM. ATPase activity of myosin correlated with speed of muscle shortening. J Gen Physiol1967;50(suppl): 197–218.
16.
TeigEDahlHAThorkelsenH. Actomyosin ATPase activity of human laryngeal muscles. Acta Otolaryngol (Stockh)1978;85:272–81.
17.
MalmgrenLTGacekRR. Histochemical characteristics of muscle fiber types in the posterior cricoarytenoid muscle. Ann Otol Rhinol Laryngol1981;90:423–9.
18.
RosenfieldDBMillerRHSessionsRBPattenBM. Morphologic and histochemical characteristics of laryngeal muscle. Arch Otolaryngol1982;108:662–6.
19.
PorterJDStrebeckSCapraNF. Botulinum-induced changes in monkey eyelid muscle. Comparison with changes seen in extraocular muscle. Arch Ophthalmol1991;109:396–404.
20.
HornAKPorterJDEvingerC. Botulinum toxin paralysis of the orbicularis oculi muscle. Types and time course of alterations in muscle structure, physiology and lid kinematics. Exp Brain Res1993;96:39–53.
21.
HarrisCPAldersonKNebekerJHoldsJBAndersonRL. Histologic features of human orbicularis oculi treated with botulinum A toxin. Arch Ophthalmol1991;109:393–5.
22.
DuchenLW. Effects of botulinum toxin on the distribution of succinate dehydrogenase and Phosphorylase in fast and slow skeletal muscles of the mouse. J Neurol Neurosurg Psychiatry1970;33:580–5.
23.
DuchenLW. An electron microscopic study of changes induced by botulinum toxin in the motor end-plates of slow and fast skeletal muscle fibres of the mouse. J Neurol Sci1971;14:47–60.
24.
DuchenLW. Changes in the electron microscopic structure of slow and fast skeletal muscle fibres of the mouse after the local injection of botulinum toxin. J Neurol Sci1971;14:61–74.
25.
KranjcBSSketeljJD'AlbisAErzenI. Long-term changes in myosin heavy chain composition after botulinum toxin A injection into rat medial rectus muscle. Invest Ophthalmol Vis Sci2001;42:3158–64.
26.
RomanulFCVan der MeulenJP. Reversal of the enzyme profiles of muscle fibres in fast and slow muscles by cross-innervation. Nature1966;212:1369–70.
27.
YellinH. Neural regulation of enzymes in muscle fibers of red and white muscle. Exp Neurol1967;19:92–103.
28.
Telerman-ToppetNBacqMKhoubesserianPCoersC. Type 2 fiber predominance in muscle cramp and exertional myalgia. Muscle Nerve1985;8:563–7.
29.
EdstromLKugelbergE. Histochemical mapping of motor units in experimentally re-innervated skeletal muscle. Experientia1969;25:1044–5.
30.
DedoHHIzdebskiKTownsendJJ. Recurrent laryngeal nerve histopathology in spastic dysphonia: A preliminary study. Ann Otol Rhinol Laryngol1977;86:806–12.
31.
CarlsooBIzdebskiKDahlqvistADomeijSDedoHH. The recurrent laryngeal nerve in spastic dysphonia. A light and electron microscopic study. Acta Otolaryngol (Stockh)1987;103:96–104.
32.
KosakiHIwamuraSYamazakiI. Histologic study of the recurrent laryngeal nerve in spasmodic dysphonia. Otolaryngol Head Neck Surg1999;120:129–33.
